Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
Pediatr Rheumatol Online J. 2012 Aug 29;10(1):30. doi: 10.1186/1546-0096-10-30.
Tocilizumab (TCZ) is the first FDA- approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3 cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant cytopenias shortly after initiation of TCZ had a history of macrophage activation syndrome. We raise the possibility that patients with a tendency towards MAS have an increased risk of developing cytopenias when treated with tocilizumab.
托珠单抗（TCZ）是首个获得美国食品药品监督管理局（FDA）批准用于治疗全身型幼年特发性关节炎（sJIA）的药物。我们报告了 3 例 sJIA 患儿在接受 TCZ 治疗后出现血细胞减少症的病例。其中 2 例患儿在开始 TCZ 治疗后不久出现严重血细胞减少症，且均有巨噬细胞活化综合征（MAS）病史。我们提出一种可能性，即倾向于发生 MAS 的患者在接受托珠单抗治疗时发生血细胞减少症的风险增加。
